Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: Correlation with drug exposure and anxiolytic efficacy

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 86-96

  Li, Yu Wen ^a,b   Hill, Geraldine ^a   Wong, Harvey ^a   Kelly, Natasha ^a   Ward, Kathryn ^a   Pierdomenico, Marie ^a   Ren, Shelly ^a   Gilligan, Paul ^a   Grossman, Scott ^a   Trainor, George ^c   Taub, Rebecca ^a   McElroy, John ^a   Zazcek, Robert ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RECEPTOR BINDING; IC 50; LATENT PERIOD; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; BINDING SITES; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; IODINE RADIOISOTOPES; MALE; PEPTIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STATISTICS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TRIAZINES;

EID: 0037382398     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.045914     Document Type: Article

References (38)

1. Aguilera G, Millan MA, Hauger RL, and Catt KJ (1987) Corticotropin-releasing factor receptors: distribution and regulation in brain, pituitary and peripheral tissues. Ann NY Acad Sci 512:48-66.
2. Altemus M, Swedo SE, Leonard HL, Richter D, Rubinow DR, Potter WZ, and Rapoport JL (1994) Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 51:794-803.
3. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, and Owens MJ (2000) Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154, 526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 294:588-597.
4. Bakthavatchalam R, Arvanitis AG, Gilligan PJ, Olson RE, Robertson DW, Trainor G, Smith SC, Fitzgerald LW, Zaczek R, Shen H, et al. (1998) The discovery of DMP695: an orally active corticotropin-releasing hormone (CRF1) receptor antagonist, in The 216th ACS National Meeting, Boston, MA, Aug 23-27; MEDI 134.
5. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, and Charney DS (1997) Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629.
6. Chalmers DT, Lovenberg TW, and De Souza EB (1995) Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15:6340-6350.
7. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, and De Souza EB (1996) Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 174:166-172.
8. De Souza EB (1987) Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci 7:88-100.
9. Gilligan PJ, Baldauf C, Cocuzza A, Chidester D, Zaczek R, Fitzgerald LW, McElroy J, Smith MA, Shen HS, Saye JA, et al. (2000b) The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl) -pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg Med Chem Lett 8:181-189.
10. Gilligan PJ, Robertson DW, and Zaczek R (2000a) Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J Med Chem 43:1641-1660.
11. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, et al. (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084.
12. 1 receptor antagonist. J Med Chem 43:449-456.
13. Heinrichs SC and De Souza EB (1999) Corticotropin-releasing factor antagonists, binding-protein and receptors: implications for central nervous system disorders. Bailliere's Best Pract Res Clin Endocrinol Metab 13:541-554.
14. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, and Grigoriadis DE (2002) Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202.
15. Hill G, Zaczek R, and Li Y-W (2001) Corticotropin releasing factor type-1 receptor occupancy of DMP696 in rat brain: ex vivo binding autoradiography. Soc Neurosci Abstr 27.
16. Kapur S, Barlow K, VanderSpek SC, Javanmard M, and Nobrega JN (2001) Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs. ex vivo. Psychopharmacology (Berl) 157:168-171.
17. Kaye WH, Berrettini WH, Gwirtsman HE, Chretien M, Gold PW, George DT, Jimerson DC, and Ebert MH (1987) Reduced cerebrospinal fluid levels of immunoreactive pro-opiomelanocortin related peptides (including β-endorphin) in anorexia nervosa. Life Sci 41:2147-2155.
18. 1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373-380.
19. 1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39:1357-1367.
20. Keller C, Bruelisauer A, Lemaire M, and Enz A (2002) Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab Dispos 30:173-176.
21. Korte SM, Korte-Bouws GA, Bohus B, and Koob GF (1994) Effect of corticotropin-releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats. Physiol Behav 56:115-120.
22. Langlois X, te Riele P, Wintmolders C, Leysen JE, and Jurzak M (2001) Use of the β-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J Pharmacol Exp Ther 299:712-717.
23. Maciag CM, Dent G, Gilligan P, He L, Dowling K, Ko T, Levine S, and Smith MA (2002) Effects of a non-peptide CRF antagonist (DMP696) on the behavioral and endocrine sequelae of maternal separation. Neuropsychopharmacology 26:574-582.
24. 1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Pyschopharmacology (Berl) 165:86-92.
25. 1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25:585-600.
26. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, and Tomisawa K (1999) Receptor binding, behavioral and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289:926-935.
27. Owens MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473.
28. Pardridge WM (1998) CNS drug design based on principles of blood-brain barrier transport. J Neurochem 70:1781-1792.
29. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, 4th ed, Academic Press, Inc., San Diego, CA.
30. Primus RJ, Yevich E, Baltazar C, and Gallager DW (1997) Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology 17:308-316.
31. Rominger DH, Rominger CM, Fitzgerald LW, Grzanna R, Largent BL, and Zaczek R (1998) Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies. J Pharmacol Exp Ther 286:459-468.
32. Sawchuk RJ and Yang Z (1999) Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 39:5-31.
33. Stenzel-Poore MP, Duncan JE, Rittenberg MB, Bakke AC, and Heinrichs SC (1996) CRH overproduction in transgenic mice: behavioral and immune system modulation. Ann NY Acad Sci 780:36-48.
34. 2 receptors in fear and anxiety. Neurosci Biobehav Rev 25:627-636.
35. 2 receptors produces anxiolytic behavior in animal models of anxiety. Brain Res 902:135-142.
36. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, and Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-166.
37. 3H]SN003) for corticotropin-releasing factor 1 (CRF1) receptors. J Pharmacol Exp Ther 305:57-69.
38. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, and Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiat Res 34:171-181.